Skip to main content
Back to Articles

Can a Single Dose of Creatine Protect Your Brain During Sleep Deprivation?

By the CreatineIQ Research Desk
Last reviewed
New Research
Brain Health
Sleep

While creatine is widely known for its physical performance benefits, emerging research highlights its critical role in brain energy homeostasis. A 2026 study published in the journal Nutrients investigated whether a single, acute dose of creatine could preserve cognitive performance during an extended period of sleep deprivation.

Key Takeaways

  • Modest Cognitive Protection: A single dose of creatine (0.2 g/kg of body weight) modestly mitigated the deterioration of logical reasoning during sleep deprivation. Effects on numerical reasoning, language-related processing speed and vigilance were less certain: they did not survive the paper's own correction for multiple comparisons.
  • Gender Differences: Females in the study showed more pronounced benefits in logic, psychomotor vigilance, and processing speed compared to males.
  • Dose Considerations: While this dose (0.2 g/kg — around 14 g for a 70 kg adult) yielded up to a 12% improvement in performance versus a placebo, the authors noted the effect was less pronounced than higher doses (0.35 g/kg) analyzed in their previous research, and describe it as "weak".
  • Fatigue Remained: While some cognitive output held up better, participants' subjective feelings of fatigue and sleepiness still increased normally as the night progressed.

The Study Design

The researchers recruited 29 healthy subjects (17 females, 12 males; aged 20–40) for a randomized, double-blind1, crossover study2.

Participants were subjected to 21 hours of sleep deprivation. After baseline cognitive measurements in the early evening, they received either a single oral dose of creatine monohydrate (0.2 g/kg) or a placebo at 9:00 PM. Cognitive performance was then reassessed at 3, 5.5, and 7.5 hours post-supplementation.

The cognitive testing battery included the Psychomotor Vigilance Test (PVT)3, working memory tasks, and complex multiple-choice tests assessing language, logic, and numerical abilities.

The Findings

The authors' rationale is that prolonged wakefulness taxes the brain's energy reserves, primarily ATP, which creatine helps regenerate — but this study measured no brain metabolism, only cognitive performance. On that measure, the pooled creatine-versus-placebo effects were modest. The paper set a Bonferroni-adjusted significance threshold (α = 0.05/8, about 0.006):

  • Logic and Processing Speed: Logic was the only pooled comparison to clear that threshold (6.1% better than placebo, p = 0.005). Numerical tasks (6.2%) and language processing speed (12.3%) also improved, but at p = 0.04, which does not.
  • Vigilance and Reaction Time: On the Psychomotor Vigilance Test (PVT), the pooled benefit was in the variability of reaction times (9.2%, p = 0.02), not in average reaction time. In the subgroup analyses, an improvement in overall mean reaction time appeared only in females (4.3%, p = 0.01). Neither clears the corrected threshold.
  • Memory Effects were Mixed: While logic showed the clearest signal, short-term memory tasks saw less consistent benefits from this specific dosage.

Analyzing the Study: Strengths & Limitations

Strengths and Reputability

The study used a double-blind, randomized, balanced crossover design, with the creatine and placebo preparations blinded and randomized by an independent pharmacy. Because every participant completed both the creatine and the placebo condition, each acts as their own control, which removes individual differences in baseline intelligence and natural sleep-loss resilience from the comparison — a meaningful advantage in a sample this size.

One detail worth noting for this site's readers: 9 of the 29 participants were vegetarians. Baseline creatine stores are typically lower on a plant-based diet, so a mixed sample of this kind may respond somewhat differently than an all-omnivore one would.

Limitations

  1. Not an Independent Replication: This is the same group's follow-up to their own earlier 0.35 g/kg study, testing a lower dose. That makes it a coherent research programme, but the 0.2 g/kg finding has not yet been reproduced by an unaffiliated lab.
  2. No Direct Brain Scans: Unlike some previous iterations of this research, this study did not use neuroimaging to directly measure brain creatine or ATP levels, relying entirely on functional cognitive outputs to infer metabolic protection.
  3. Acute vs. Chronic Supplementation: The study tested a large, single dose right before the sleep deprivation period. This does not necessarily reflect the effects of standard daily creatine supplementation (e.g., 3-5g daily) where muscle and brain stores are fully saturated over time.
  4. Small Sample Size: With 29 participants the study is small, and the sex-difference finding is a subgroup comparison within that small sample — the kind of result that most often fails to replicate. Treat it as a lead for future work rather than an established difference.

Conflicts of Interest

Two things are worth separating here. On funding, the study is clean: expenses for the entire study and the personnel budget for all authors were financed by Forschungszentrum Jülich, the German public research centre where the work was carried out. The creatine used was Creavitalis, a micronized monohydrate made by AlzChem, but the paper reports it as the product used rather than as a sponsorship.

Separately, senior author A. Drzezga declares an extensive set of industry relationships — research support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, Sofie, Eisai and Novartis/AAA; speaker honoraria and advisory board roles including Sanofi, Biogen, Novo Nordisk and Bayer Vital; stock in Siemens Healthineers and Lantheus; and a pending patent on a PET imaging tracer. These sit in neuroimaging and radiopharmaceuticals rather than the supplement industry, so they bear less directly on a creatine result than a supplement-company relationship would. The remaining authors declare no conflicts.

Conclusion

For individuals facing acute sleep deprivation—such as shift workers, medical residents, or first responders—a single dose of creatine may offer a modest buffer for some kinds of reasoning, though the authors themselves describe the effect as weak. In this study the clearest benefit was in logic tasks; the effects on numerical reasoning, processing speed and vigilance were less certain and did not survive correction for multiple comparisons, and the energy-supply explanation was not measured directly.

These findings remain preliminary, though. It is worth being concrete about what the dose means in practice: 0.2 g/kg is roughly 14 g for a 70 kg adult, taken at once — several times a normal daily maintenance dose, and not a protocol anyone should adopt casually. With 29 participants, a single research group, and functional cognitive tests standing in for direct measurement of brain energy, this is a modest, preliminary result rather than an established one. It earns a place in the evidence base for acute creatine dosing; it does not yet settle it.

References

  1. Gordji-Nejad A, Matusch A, Hengstler L, et al. Single-Dose Creatine Reduces Sleep Deprivation-Induced Deterioration in Cognitive Performance. Nutrients (2026). DOI: 10.3390/nu18081192

Glossary

  1. Double-blind: Neither the participants nor the researchers running the cognitive tests know who is receiving the active treatment or placebo during the experiment. ↩

  2. Crossover study: A study design in which all participants receive both the treatment and the placebo in sequential, randomized order across different sessions (nights). ↩

  3. Psychomotor Vigilance Test (PVT): A sustained-attention, reaction-timed task that measures the speed with which subjects respond to a visual stimulus, highly sensitive to sleep deprivation. ↩